摘要 |
<p>Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize ß-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.</p> |
申请人 |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY;THE GENERAL HOSPITAL CORPORATION;THE BROAD INSTITUTE;HAGGARTY, STEPHEN, J.;FASS, DANIEL;PAN, JENNIFER;KETTERMAN, JOSH;HOLSON, EDWARD;PETRYSHEN, TRACEY, LYNN;LEWIS, MICHAEL, C. |
发明人 |
HAGGARTY, STEPHEN, J.;FASS, DANIEL;PAN, JENNIFER;KETTERMAN, JOSH;HOLSON, EDWARD;PETRYSHEN, TRACEY, LYNN;LEWIS, MICHAEL, C. |